Search Results

At CSL, we value workplace health, safety and wellbeing for all of our employees. We employ dedicated Employee, Health & Safety (EHS) managers and teams at all our manufacturing sites.

https://corporateresponsibility.csl.com/workplace/health-and-safety

CSL is committed to the development, manufacture and supply of high quality, safe products that save lives and improve the health and wellbeing of patients with serious diseases.

https://corporateresponsibility.csl.com/safety

CSL is committed to the development, manufacture and supply of high quality, safe products that save lives and improve the health and wellbeing of patients with serious diseases.

https://corporateresponsibility.csl.com/safety/plasma-therapies-and-vaccines

CSL has an Environment, Health, Safety and Sustainability (EHS2) Strategic Plan which ensures its facilities operate to industry and regulatory standards.

https://corporateresponsibility.csl.com/environment

CSL conducts clinical trials in accordance with the current Guideline for Good Clinical Practice (GCP) of the International Conference on Harmonisation (ICH).

https://corporateresponsibility.csl.com/innovation/research-practices/bioethical-issues

CSL is committed to the development, manufacture and supply of high quality, safe products that save lives and improve the health and wellbeing of patients with serious diseases.

https://corporateresponsibility.csl.com/safety/plasma-donations-and-donors

For product safety and quality, applicable laws and standards, completing all assigned management process.

https://corporateresponsibility.csl.com/-/media/csl/documents/crbp-languages/csl_crbp2021_english_external.pdf

A member firm of Ernst & Young Global Limited Liability limited by a scheme approved under Professional Standards Legislation Page 2 ► evaluating the suitability of the Criteria and checking it has been appropriately applied in preparing the Selected Disclosures ► inquiring of site personnel to identify risks of underreporting and quality controls to address these risks ► undertaking data analytics to check the reasonableness of the data supporting disclosures ► reviewing data and performing recalculations of performance metrics to check reported quantities ► on a judgemental sampling basis, requesting and agreeing source evidence to data ► comparing classification of safety incidents against the CSL Standard Operating Procedures to confirm accuracy and consistency ► obtaining audit close reports to confirm existence of quality audits of suppliers and regulatory audits ► checking regulatory body websites to confirm accuracy and completeness of safety related recall reporting ► checking aggregation of site-based Selected Disclosures and transcription to the Report ► evaluating the appropriateness of the presentation relating to the Selected Disclosures and whether the disclosed information is consistent with our understanding of corporate responsibility management and performance at CSL.

https://corporateresponsibility.csl.com/-/media/corporate-responsibility/documents/csl-final-assurance-statement-2021.pdf

CSL’s Global CR Committee has overall responsibility for the materiality process and executes a global materiality assessment on a biennial basis. In 2017/18, we concluded our third such assessment and followed the Global Reporting Initiative (GRI) standards of sustainability context, materiality, completeness and stakeholder inclusiveness through our process of identification, review and prioritisation. The application and disclosure of our materiality process against the GRI materiality principle definition was externally assured by Ernst & Young.

https://corporateresponsibility.csl.com/approach/material-topics

CSL regards stakeholder engagement as a foundation of corporate responsibility, and have identified our key stakeholders as patient groups, employees, investors, regulators, suppliers, government, healthcare professionals, plasma donors, business partners and the academic and scientific community.

https://corporateresponsibility.csl.com/approach/stakeholder-engagement